Eupraxia Pharmaceuticals (NASDAQ:EPRX) Sees Large Volume Increase – What’s Next?

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) saw strong trading volume on Friday . 3,055,170 shares were traded during trading, an increase of 996% from the previous session’s volume of 278,730 shares.The stock last traded at $8.01 and had previously closed at $7.50.

Analysts Set New Price Targets

Several equities analysts recently commented on EPRX shares. Zacks Research raised shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. Oppenheimer assumed coverage on Eupraxia Pharmaceuticals in a report on Thursday, June 25th. They issued an “outperform” rating and a $17.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Finally, Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Eupraxia Pharmaceuticals Price Performance

The firm’s fifty day moving average price is $6.64 and its 200 day moving average price is $6.99. The firm has a market capitalization of $520.49 million, a PE ratio of -7.82 and a beta of 1.07. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. As a group, equities analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.87 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Persistent Asset Partners Ltd purchased a new stake in shares of Eupraxia Pharmaceuticals during the second quarter worth $25,000. BlackRock Inc. purchased a new position in shares of Eupraxia Pharmaceuticals during the second quarter worth approximately $40,000. Aptus Capital Advisors LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at approximately $76,000. Guardian Wealth Advisors LLC NC purchased a new stake in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at about $76,000. Finally, Integrated Wealth Concepts LLC acquired a new position in Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $71,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.